Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
3.230
-0.360 (-10.03%)
At close: Sep 3, 2025, 4:00 PM
3.260
+0.030 (0.93%)
After-hours: Sep 3, 2025, 4:00 PM EDT
Company Description
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company is based in Santa Barbara, California.
Protagenic Therapeutics, Inc.
Country | United States |
Founded | 1994 |
IPO Date | Jan 5, 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 3 |
CEO | Barrett Evans |
Contact Details
Address: 701 Anacapa Street, Suite C Santa Barbara, California 93101 United States | |
Phone | (805) 699-5596 |
Website | phytanix.com |
Stock Details
Ticker Symbol | PTIX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001022899 |
CUSIP Number | 74365N301 |
ISIN Number | US74365N2027 |
Employer ID | 06-1390025 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Barrett Evans | President, Chief Executive Officer and Director |
Dr. Garo H. Armen Ph.D. | Co-Founder and Executive Chairman of the Board |
Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer and Secretary |
Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer |
Dr. Andrew Slee Ph.D. | Chief Development Officer |
Colin G. Stott B.Sc. | Chief Operating Officer and Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 28, 2025 | 8-K/A | [Amend] Current report |
Aug 25, 2025 | SCHEDULE 13G/A | Filing |
Aug 22, 2025 | 8-K | Current Report |
Aug 14, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Aug 13, 2025 | 8-K | Current Report |
Jul 30, 2025 | 8-K | Current Report |
Jul 24, 2025 | 8-K | Current Report |
Jul 8, 2025 | SCHEDULE 13G | Filing |
Jun 27, 2025 | 8-K | Current Report |
May 21, 2025 | 8-K | Current Report |